H.R. 1063 — Drug Competition Act of 2001

Summary

Drug Competition Act of 2001 - Requires brand name drug manufacturers and generic drug manufacturers to notify the Federal Trade Commission and the Attorney General of agreements regarding the sale or manufacture of generic drugs which could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.

Full Text

Legislative Actions

2001-03-15
Introduced in House
2001-03-15
Introduced in House
2001-03-15
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2001-03-15
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2001-03-15
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2001-03-22
Referred to the Subcommittee on Health.

Drug Competition Act of 2001

Sponsors

Subjects

Summary

Full Text

Legislative Actions

Ask about this bill